A Phase 2, Prospective, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of SJX-653 in Postmenopausal Women With Moderate to Severe Vasomotor Symptoms
Latest Information Update: 04 Aug 2022
Price :
$35 *
At a glance
- Drugs SJX-653 (Primary)
- Indications Hot flashes; Vasomotor symptoms
- Focus Therapeutic Use
- Sponsors Sojournix
- 10 Mar 2021 Status changed from recruiting to discontinued.
- 08 Dec 2020 According to a Sojournix media release, results are expected in the second half of 2021.
- 08 Dec 2020 According to a Sojournix media release, this trial was paused earlier this year due to COVID-19 and has now been amended and resumed with a streamlined design and integration of remote clinical trial techniques to reduce in-person contact and help safeguard the safety of patients and study personnel during the pandemic.